Tiantan Biotech announced on the evening of August 30 that the company's holding subsidiary, Chengdu Rongsheng Pharmaceutical Co., Ltd., plans to acquire 100% of the shares of CSL BEHRING ASIA PACIFIC LIMITED (“CSL Asia Pacific”) wholly-owned subsidiary (“CSL Asia Pacific”) for a total amount of US$185 million. Among them, the share purchase price was US$138 million. Chengdu Rongsheng provided loans to Zhongyuan Reed to repay CSL Asia Pacific's shareholder loans to Zhongyuan Reed. Zhongyuan Reed is a blood products company. After the transaction is completed, the company will add a new blood products manufacturer and add 5 additional active plasma collection stations, which will help further develop plasma resources, expand the scale of plasma collection and production, and enhance the company's competitive strength in the blood products industry.

Tiantan Biotech announced on the evening of August 30 that the company's holding subsidiary, Chengdu Rongsheng Pharmaceutical Co., Ltd., plans to acquire 100% of the shares of CSL BEHRING ASIA PACIFIC LIMITED (“CSL Asia Pacific”) wholly-owned subsidiary (“CSL Asia Pacific”) for a total amount of US$185 million. Among them, the share purchase price was US$138 million. Chengdu Rongsheng provided loans to Zhongyuan Reed to repay CSL Asia Pacific's shareholder loans to Zhongyuan Reed. Zhongyuan Reed is a blood products company. After the transaction is completed, the company will add a new blood products manufacturer and add 5 additional active plasma collection stations, which will help further develop plasma resources, expand the scale of plasma collection and production, and enhance the company's competitive strength in the blood products industry.